Yahoo
NSE - Delayed Quote INR

Emcure Pharmaceuticals Limited (EMCURE.NS)

1,883.50 +11.70 (+0.63%)
At close: 3:29:52 PM GMT+5:30
EMCURE.NS Q2 2027 earnings call
November 3, 2026 at 4:00 PM GMT+5:30
Chart Range Bar
Loading chart for EMCURE.NS
  • Previous Close 1,871.80
  • Open 1,891.30
  • Bid --
  • Ask --
  • Day's Range 1,853.60 - 1,899.90
  • 52 Week Range 1,306.50 - 2,100.70
  • Volume 86,619
  • Avg. Volume 149,430
  • Market Cap (intraday) 357.32B
  • Beta (5Y Monthly) -0.00
  • PE Ratio (TTM) 35.30
  • EPS (TTM) 53.35
  • Earnings Date --
  • Forward Dividend & Yield 3.60 (0.19%)
  • Ex-Dividend Date Sep 4, 2026
  • 1y Target Est 2,229.38

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M, Orofer Fcm, Maxtra, Clexane, Metpure-Xl, Amaryl, Spegra, Feronia-Xt, Cardace, Pause, Lornit, Targocid, Orofer-S, Lasilactone, Gros, Orofer-Xt Liq, And Tenectase brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

www.emcure.com

6,914

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

EMCURE.NS
38.30%
S&P BSE SENSEX (^BSESN)
11.18%

1-Year Return

EMCURE.NS
43.09%
S&P BSE SENSEX (^BSESN)
9.82%

3-Year Return

EMCURE.NS
42.15%
S&P BSE SENSEX (^BSESN)
18.12%

5-Year Return

EMCURE.NS
42.15%
S&P BSE SENSEX (^BSESN)
26.09%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 25.8B
Earnings 2.94B
Profit Margin 11.39%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
5B
10B
15B
20B
25B
10.0%
10.5%
11.0%

Analyst Insights

View More

Analyst Price Targets

1,900.00
2,229.38 Average
1,883.50 Current
2,362.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.44%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    96.83B

  • Net Income Avi to Common (ttm)

    10.11B

  • Diluted EPS (ttm)

    53.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.48B

  • Total Debt/Equity (mrq)

    30.57%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: